← All trials
NCT03281083
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2014
- Primary completion
- Jul 28, 2016
- Completion date
- Jul 28, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 29
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- Nanyang Technological UniversityCollaborator
- National University of SingaporeCollaborator
- Duke UniversityReponsible party - principal investigator
- Duke UniversityOverall official - principal investigator
- Singapore General HospitalCollaborator
- Changi General HospitalCollaborator
- Khoo Teck Puat HospitalCollaborator
- Ng Teng Fong General HospitalCollaborator
- Singapore Bioimaging ConsortiumCollaborator
- Singapore Clinical Research InstituteCollaborator
- Singapore Institute for Clinical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.